Hardman & Co Research Highlights Tissue Regenix's Impressive Growth Streak

Hardman & Co has published a research report on Tissue Regenix Group PLC (TRX), marking the company's achievement of more than 20% growth for six consecutive reporting periods. The focus of TRX on the development and commercialization of proprietary processing technologies for soft tissue (dCELL®) and bone (BioRinse®) repairs has played a crucial role in this success. The company's diverse portfolio caters to biosurgery, orthopaedics, and dental markets.

Investments in tissue processing, manufacturing capacity, and the collaboration with strong commercial partners, combined with the implementation of its "4S" strategy, have cumulated into a robust growth trajectory. Notably, TRX attained EBITDA positivity in 2023, and projections for 2024 anticipate the company becoming fully profitable and cash-generative. This financial health will enable further expansion through Phase 2 starting in 2025.